# Greenwich LifeSciences, Inc. (GLSI)

> Source: Nexqual · https://nexqual.com/GLSI · data as of 2026-11-18 21:00 UTC · cite as "Nexqual, Greenwich LifeSciences, Inc. (GLSI), nexqual.com/GLSI" · informational, not investment advice.

## What changed for GLSI since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).

- Greenwich LifeSciences, Inc. (GLSI) stock went from USD 11.48 (close of the week of Aug 25, 2025, split-adjusted) to USD 20.58, a +79.3% price change; the S&P 500 (SPY) moved +14.7% over the same period.

**Price:** USD 20.58 (+10.05% on the day) · last close of Nov 18, 2026; US market after hours, not a live price. Prev close 18.7 · day 18.24–21.98 · 52w 7.78–34.1 · market cap $302M · NCM

## Key facts
- Insider open-market purchases, last ~7 months: 3 Form 4 filings, $97K; 0 by opportunistic insiders, 3 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 57.5 (range 45–70).
- Total return with dividends: 1Y +147.9% vs S&P 500 +11.4%; 5Y -41.4% vs S&P 500 +66.5%.
- Latest earnings report: 2026-11-16 (next date not yet announced).
- Dividend: GLSI paid no cash dividend in the last five years.
- Short interest: 20.64% of float (as of 2026-10-30), 11.5 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$4.6M | -$8.0M | -$9.3M | -$17.6M | -$19.4M | -$24.8M |
| Net income | -$4.6M | -$7.8M | -$8.9M | -$17.4M | -$19.4M | -$24.6M |
| EPS (diluted) | -$0.35 | -$0.61 | -$0.69 | -$1.34 | -$1.43 | — |
| Cash + short-term investments | $27.2M | $13.5M | $7.0M | $4.1M | $6.2M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Sep 30, 2026)
Earnings yield -8.19%

## Insider purchases (SEC Form 4, open-market, last ~7 months)
3 purchases, $97K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-07-28…2026-07-29 | Patel Snehal | CEO and CFO | 2,200 | $30K | 13.43 | Routine (bought in Apr each year 2023–2025; this trade is outside those months) |
| 2026-07-27 | Patel Snehal | CEO and CFO | 1,500 | $20K | 13.62 | Routine (bought in Apr each year 2023–2025; this trade is outside those months) |
| 2026-07-23…2026-07-24 | Patel Snehal | CEO and CFO | 3,600 | $47K | 13.06 | Routine (bought in Apr each year 2023–2025; this trade is outside those months) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 57.5 (low 45, high 70).

## Total return (dividends reinvested)
|  | 1Y (from 2025-11-18) | 5Y (from 2021-11-15) |
|---|---|---|
| Total return | +147.9% | -41.4% |
| S&P 500 (SPY) | +11.4% | +66.5% |
| Per year | +148.1% | -10.1% |
| Volatility (annualized) | 110.4% | 68.5% |
| Max drawdown | -61.9% (Jan 2026→Jul 2026) | -78.9% (Nov 2021→Jun 2022) |

## Dividends
GLSI paid no cash dividend in the last five years.

## Short interest
1,578,166 shares sold short, 20.64% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 1,580,950 shares (-0.2%). Days to cover: 11.5 (short shares ÷ average daily volume).

## Peers (Biotechnology)
KOD (Kodiak Sciences Inc) USD 97.81 +1.04% · BLTE (Belite Bio, Inc) USD 156.23 -0.94% · ORKA (Oruka Therapeutics, Inc.) USD 95.74 -0.60% · IBRX (ImmunityBio, Inc.) USD 6.7 +7.03% · IMVT (Immunovant, Inc.) USD 33.17 -0.12% · CGON (CG Oncology, Inc.) USD 80 +1.34%

## More
Full page: https://nexqual.com/GLSI · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-12-31) | $-0.42 | $-0.35 | −$0.07 | $0 | 2 |
| Next quarter (ends 2027-03-31) | $-0.43 | $-0.30 | −$0.13 | $0 | 2 |
| Current fiscal year (ends 2026-12-31) | $-1.48 | $-1.39 | −$0.09 | $0 | 2 |
| Next fiscal year (ends 2027-12-31) | $-1.80 | $-1.17 | −$0.63 | $0 | 2 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Sep 30, 2026 | −$0.40 | −$0.33 | Miss −21.2% | — |
| — | Quarter ended Jun 30, 2026 | −$0.27 | −$0.33 | Beat +18.2% | — |
| — | Quarter ended Mar 31, 2026 | −$0.39 | −$0.35 | Miss −11.4% | — |
| — | Quarter ended Dec 31, 2025 | −$0.58 | −$0.32 | Miss −81.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-11-16 | 10-Q | Quarterly report · period ended Sep 30, 2026 | https://www.sec.gov/Archives/edgar/data/1799788/000149315226052438/0001493152-26-052438-index.htm |
| 2026-10-26 | DEFA14A | Additional proxy material | https://www.sec.gov/Archives/edgar/data/1799788/000149315226048563/0001493152-26-048563-index.htm |
| 2026-10-26 | DEF 14A | Proxy statement (pay, board, votes) · period ended Oct 26, 2026 | https://www.sec.gov/Archives/edgar/data/1799788/000149315226048537/0001493152-26-048537-index.htm |
| 2026-08-11 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1799788/000149315226037147/0001493152-26-037147-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.
